RESV anti-inflammatory activity has been well documented in different cancer cell lines, and it is based on different mechanisms by which it inhibits different inflammatory pathways such as COX-2, NF-κB and activator protein 1 (AP1) [117,120]. The gene discussed is JUN; the disease is cancer.